Cellectar Biosciences Inc. secured patents covering the method of use for its CLR 131 and CLR 125 compounds in radiotherapy in the U.S.

The patent runs through 2025 and covers radiotherapy applications for multiple tumor types, including lung and intestinal.

Cellectar also recently received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers, as well as associated cancer stem cells.